Have a personal or library account? Click to login
A comprehensive review of the association between sarcopenia and COPD Cover

A comprehensive review of the association between sarcopenia and COPD

Open Access
|Mar 2026

References

  1. SUN Y., ZHANG L., CAI H., CHEN Y. Editorial: Osteoporosis, sarcopenia and muscle-bone crosstalk in COPD. Front Physiol. 2022; 13:1040693.
  2. BENZ E., et al. Sarcopenia in COPD: A systematic review and meta-analysis. Eur Respir Rev. 2019; 28(154).
  3. KALUŹNIAK-SZYMANOWSKA A., KRZYMIŃSKA-SIEMASZKO R., DESKUR-ŚMIELECKA E., LEWANDOWICZ M., KACZMAREK B., WIECZOROWSKA-TOBIS K. Malnutrition, sarcopenia, and malnutrition-sarcopenia syndrome in older adults with COPD. Nutrients. 2022; 14(1).
  4. XIANG Y., LUO X. Extrapulmonary comorbidities associated with chronic obstructive pulmonary disease: A review. Int J Chron Obstruct Pulmon Dis. 2024; 19:567–78.
  5. CRUZ-JENTOFT A.J., et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019; 48(1):16–31.
  6. BAUER J., et al. Sarcopenia: A time for action. An SCWD position paper. J Cachexia Sarcopenia Muscle. 2019; 10(5):956–61.
  7. VAN BAKEL S.I.J., GOSKER H.R., LANGEN R.C., SCHOLS A.M.W.J. Towards personalized management of sarcopenia in COPD. 2021.
  8. LOCQUET M., BRUYÈRE O., LENGELÉ L., REGINSTER J.Y., BEAUDART C. Relationship between smoking and the incidence of sarcopenia: The SarcoPhAge cohort. Public Health. 2021; 193:101–8.
  9. ZHOU J., et al. Risk factors of sarcopenia in COPD patients: A meta-analysis. Int J Chron Obstruct Pulmon Dis. 2024; 19:1613–22.
  10. TRAJANOSKA K., et al. Sarcopenia and its clinical correlates in the general population: The Rotterdam Study. J Bone Miner Res. 2018; 33(7):1209–18.
  11. GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE. Global Initiative for Chronic Obstructive Lung Disease – GOLD. 2024.
  12. MALTAIS F., et al. An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2014; 189(9).
  13. BARREIRO E., JAITOVICH A. Muscle atrophy in chronic obstructive pulmonary disease: molecular basis and potential therapeutic targets. J Thorac Dis. 2018; 10(Suppl 12):S1415–24.
  14. HENROT P., et al. Main pathogenic mechanisms and recent advances in COPD peripheral skeletal muscle wasting. Int J Mol Sci. 2023; 24(7).
  15. SHARANYA A., CIANO M., WITHANA S., KEMP P.R., POLKEY M.I., SATHYAPALA S.A. Sex differences in COPD-related quadriceps muscle dysfunction and fibre abnormalities. Chron Respir Dis. 2019; 16.
  16. BONE A.E., HEPGUL N., KON S., MADDOCKS M. Sarcopenia and frailty in chronic respiratory disease: lessons from gerontology. 2017.
  17. KIM S.H., SHIN M.J., SHIN Y.B., KIM K.U. Sarcopenia associated with chronic obstructive pulmonary disease. J Bone Metab. 2019;26(2):65–74.
  18. MA K., HUANG F., QIAO R., MIAO L. Pathogenesis of sarcopenia in chronic obstructive pulmonary disease. Front Physiol. 2022; 13:850964.
  19. DA COSTA T.M.R.L., COSTA F.M., MOREIRA C.A., RABELO L.M., BOGUSZEWSKI C.L., BORBA V.Z.C. Sarcopenia in COPD: relationship with COPD severity and prognosis. J Bras Pneumol. 2015; 41(5):415–21.
  20. ATEŞ F., MARQUETAND J., ZIMMER M. Detecting age-related changes in skeletal muscle mechanics using ultrasound shear wave elastography. Sci Rep. 2023; 13(1):20062.
  21. ZHANG L., SUN Y. Muscle-bone crosstalk in chronic obstructive pulmonary disease. Front Endocrinol (Lausanne). 2021; 12.
  22. MANCEAU M., et al. Myostatin promotes the terminal differentiation of embryonic muscle progenitors. Genes Dev. 2008; 22(5):668–81.
  23. SANCHO-MUÑOZ A., GUITART M., RODRÍGUEZ D.A., GEA J., MARTÍNEZ-LLLORENS J., BARREIRO E. Deficient muscle regeneration potential in sarcopenic COPD patients: role of satellite cells. J Cell Physiol. 2021; 236(4):3083–98.
  24. CAVAILLÈS A., et al. Comorbidities of COPD. Eur Respir Rev. 2013; 22(130):454–75.
  25. Y M, DAVE A.K., PATEL S.S., PARBAT R., SHAH V., GANDHI R. Association between sarcopenia and chronic renal failure (overt and concealed) in chronic obstructive pulmonary disease (COPD) patients: a cross-sectional study. Cureus. 2023; 15(10).
  26. VESTBO J., et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med. 2006; 173(1):79–83.
  27. VERMEEREN M.A.P., et al. Prevalence of nutritional depletion in a large outpatient population of patients with COPD. Respir Med. 2006; 100(8):1349–55.
  28. RUTTEN E.P.A., et al. Quantitative CT: associations between emphysema, airway wall thickness and body composition in COPD. Pulm Med. 2011; 2011:419328.
  29. DONINI L.M., et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Obes Facts. 2022; 15(3):321.
  30. OZCAKIR S., SIGIRLI D., URSAVAS A., UZASLAN E. COPD and osteoporosis: associated factors in patients treated with inhaled corticosteroids. Int J Chron Obstruct Pulmon Dis. 2020; 15:2441–48.
  31. LEDUC-GAUDET J.P., HUSSAIN S.N.A. Muscle wasting in chronic obstructive pulmonary disease: not enough autophagy? Am J Respir Cell Mol Biol. 2022; 66(6):587–88.
  32. BAHAT G., OREN M.M., YILMAZ O., KILIÇ C., AYDIN K., KARAN M.A. Comparing SARC-F with SARC-CalF to screen sarcopenia in community living older adults. J Nutr Health Aging. 2018; 22(9):1034–38.
  33. CHO M.-R., LEE S., SONG S.-K. A review of sarcopenia pathophysiology, diagnosis, treatment and future direction. J Korean Med Sci. 2022; 37(18).
  34. YUAN S., LARSSON S.C. Epidemiology of sarcopenia: prevalence, risk factors, and consequences. Metabolism. 2023; 144.
  35. VAN ANCUM J.M., ALCAZAR J., MESKERS C.G.M., NIELSEN B.R., SUETTA C., MAIER A.B. Impact of using the updated EWGSOP2 definition in diagnosing sarcopenia: a clinical perspective. Arch Gerontol Geriatr. 2020; 90.
  36. FERNANDES S., et al. Cutoff points for grip strength in screening for sarcopenia in community-dwelling older adults: a systematic review. J Nutr Health Aging. 2022; 26(5):452–60.
  37. PAPADOPOULOU S.K., TSINTAVIS P., POTSAKI G., PAPANDREOU D. Differences in the prevalence of sarcopenia in community-dwelling, nursing home and hospitalized individuals: a systematic review and meta-analysis. J Nutr Health Aging. 2020; 24(1):83–90.
  38. SHAFIEE G., KESHTKAR A., SOLTANI A., AHADI Z., LARIJANI B., HESHMAT R. Prevalence of sarcopenia in the world: a systematic review and meta-analysis of general population studies. J Diabetes Metab Disord. 2017; 16(1):1–10.
  39. ACHAMRAH N., et al. Comparison of body composition assessment by DXA and BIA according to the body mass index: a retrospective study on 3655 measures. PLoS One. 2018; 13(7):e0200465.
  40. SEPÚLVEDA-LOYOLA W., OSADNIK C., PHU S., MORITA A.A., DUQUE G., PROBST V.S. Diagnosis, prevalence, and clinical impact of sarcopenia in COPD: a systematic review and meta-analysis. 2020.
  41. MATKOVIC Z., et al. Easy to perform physical performance tests to identify COPD patients with low physical activity in clinical practice. Int J Chron Obstruct Pulmon Dis. 2020; 15:921–29.
DOI: https://doi.org/10.2478/rjim-2026-0003 | Journal eISSN: 2501-062X | Journal ISSN: 1220-4749
Language: English
Submitted on: Apr 16, 2025
|
Published on: Mar 2, 2026
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2026 Tănase Andreea Mădălina, Florentina Gherghiceanu, Beatrice Mahler, Octavian Andronic, published by N.G. Lupu Internal Medicine Foundation
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

AHEAD OF PRINT